Arcellx (ACLX) EBITDA (2021 - 2025)
Arcellx (ACLX) recorded quarterly EBITDA of -$58.0 million in Q4 2025, down 4.5% quarter-over-quarter from -$55.5 million in Q3 2025, and down 20.45% on a YoY basis from -$72.9 million in Q4 2024.
Arcellx (ACLX) EBITDA (2021 - 2025) Analysis & Trends
Arcellx's EBITDA history runs 5 years deep, the most recent figure standing at -$58.0 million for Q4 2025.
- In Q4 2025, EBITDA fell 20.45% year-over-year to -$58.0 million; the TTM figure through Dec 2025 stood at -$228.9 million (down 113.87% YoY), while the FY2025 annual figure was -$228.9 million, down 113.87% from the prior year.
- EBITDA was -$58.0 million for Q4 2025 at Arcellx, down from -$55.5 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of $20.5 million in Q4 2023 to a low of -$93.0 million in Q3 2022.
- Historically, EBITDA has averaged -$33.0 million across 5 years, with a median of -$27.3 million in 2023.
- The sharpest annual moves came in 2023 and 2025: EBITDA soared 152.7% in 2023, then tumbled 656.56% in 2025.
- A 5-year view of EBITDA shows it stood at -$20.7 million in 2021, then tumbled by 87.64% to -$38.8 million in 2022, then soared by 152.7% to $20.5 million in 2023, then sank by 335.3% to -$48.1 million in 2024, then retreated by 20.45% to -$58.0 million in 2025.
- The last three EBITDA figures came in at -$58.0 million (Q4 2025), -$55.5 million (Q3 2025), and -$53.0 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.92 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.63 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.44 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -752,618.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | -57.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -57.98 Mn |
| Sep 30, 2025 | -55.48 Mn |
| Jun 30, 2025 | -53.02 Mn |
| Mar 31, 2025 | -62.47 Mn |
| Dec 31, 2024 | -48.13 Mn |
| Sep 30, 2024 | -23.18 Mn |
| Jun 30, 2024 | -27.48 Mn |
| Mar 31, 2024 | -8.26 Mn |
| Dec 31, 2023 | 20.46 Mn |
| Sep 30, 2023 | -39.39 Mn |
| Jun 30, 2023 | -23.95 Mn |
| Mar 31, 2023 | -27.04 Mn |
| Dec 31, 2022 | -38.81 Mn |
| Sep 30, 2022 | -93.01 Mn |
| Jun 30, 2022 | -30.99 Mn |
| Mar 31, 2022 | -26.07 Mn |
| Dec 31, 2021 | -20.69 Mn |
| Sep 30, 2021 | -17.10 Mn |
| Jun 30, 2021 | -15.93 Mn |
| Mar 31, 2021 | -11.28 Mn |